Antipsychotic medication
Clomacran Trade names Devryl, Olaxin,[ 1] Develar[ 2] [ 3] ATC code Legal status
3-(2-Chloro-9,10-dihydroacridin-9-yl)-N ,N -dimethylpropan-1-amine
CAS Number PubChem CID ChemSpider UNII ChEBI ChEMBL CompTox Dashboard (EPA ) Formula C 18 H 21 Cl N 2 Molar mass 300.83 g·mol−1 3D model (JSmol ) Density 1.120 g/cm3 g/cm3 [ 1]
CN(C)CCCC1C2=CC=CC=C2NC3=C1C=C(C=C3)Cl
InChI=1S/C18H21ClN2/c1-21(2)11-5-7-14-15-6-3-4-8-17(15)20-18-10-9-13(19)12-16(14)18/h3-4,6,8-10,12,14,20H,5,7,11H2,1-2H3
Y Key:JFRLWWDJCFYFSU-UHFFFAOYSA-N
Y
Clomacran is an antipsychotic drug of the dihydroacridine class, developed in the 1970s[ 2] by the pharmaceutical company Smith, Kline & French (now GlaxoSmithKline ) under the brand names Devryl and Olaxin.[ 1]
It was used to treat schizophrenia in the 1970s.[ 6] It was withdrawn from the market in the UK, due to liver toxicity, in 1982.[ 4] [ 7] [ 8]
^ a b c "Clomacran | 5310-55-4" . ChemicalBook . Retrieved 2023-08-25 .
^ a b Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs . Boston, MA: Springer US. p. 297. doi :10.1007/978-1-4757-2085-3 . ISBN 978-1-4757-2087-7 .
^ "Substâncias e remédios sob controle" [Substances and drugs under control] (PDF) . Jornal do Brasil (in Brazilian Portuguese). 1986-11-05. p. 14. Archived (PDF) from the original on 2023-08-08. Retrieved 2023-08-08 .
^ a b Dixit N, Patel C, Bhavsar M, Patel S, Rawal R, Solanki H (2022-05-02). "Quantitative Structure-activity Relationship (QSAR) study of Liver Toxic Drugs" . International Association of Biologicals and Computational Digest . 1 : 63–71. doi :10.56588/iabcd.v1i1.17 . eISSN 2583-3995 .
^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-03 .
^ Pecknold JC, Ban TA, Lehmann HE, Climan M (June 1975). "Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods". International Journal of Clinical Pharmacology and Biopharmacy . 11 (4): 299–303. PMID 1099021 .
^ "Clomacran" . PubChem . U.S. National Library of Medicine. Retrieved 2023-08-25 .
^ Andrews EB, Moore N, eds. (2014). Mann's Pharmacovigilance (1st ed.). Wiley. doi :10.1002/9781118820186 . ISBN 978-0-470-67104-7 .